Феохромоцитома

феохромоцитома, эпидемиология, патогенез, диагностика, лечение

1. Platts J.K., Drew P.J., Harvey J.N. Death from phaeochromocytoma: lessons from a post-mortem survey. J R Coll Physicians London 1995; 29:299–306.

2. McNeil A.R., Blok B.H., Koelmeyer T.D. et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N J Med 2000; 30: 6: 648-652.

3. Sutton M.G., Sheps S.G., Lie J.T. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 1981;56:354–360.

4. Кушаковский М.С. Феохромоцитомы. Гипертоническая болезнь и вторичные артериальные гипертензии. Л: Медицина 1983; 239-250.

5. Калинин А.П., Казанцева И.А., Полякова Г.А. Надпочечниковые и вненадпочечниковые феохромоцитомы. Учебное пособие. М 1998; 36.

6. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. М: Практическая медицина 2005; 216.

7. Кузнецов Н.С., Бельцевич Д.Г., Лысенко М.А. Феохромоцитома. Рус врач 2002; 7.

8. Bravo E.L., Tagle R. Pheochromocytoma: state of-the-art and future prospects. Endocr Rev 2003;24: 539-553.

9. Neumann H.P.H. et al. Germ-line mutations in nonsyndromic pheochromocytoma. New Engl J Med 2002; 346: 1459-1466.

10. Gimenez-Roqueplo A.P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63: 5615-5621.

11. Eisenhofer G. et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340: 1872-1879.

12. Lack E.E. et al. Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 2003; 34: 112-113.

13. Maher E.R. et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991; 443-447.

14. Eisenhofer G. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83: 2175-2185.

15. Goldstein R.E., O'Neill J.A., George W. et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 6: 755-759.

16. Eisenhofer G. et al. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 2003; 14: 193-212.

17. Lenders J.W. et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434.

18. Guller U. et al. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 2006; 243: 102-107.

19. Furuta N. et al. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999; 6: 119-124.

20. Ilias I. et al. 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the evaluation of patients with pheochromocytoma. Abstract P3-511. Presented at the 84th Annual Meeting of the Endocrine Society, 19-22.06.02, San Fransisco, CA 2002.

21. Orlo H., Clark et al. Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2008; 1. www.nccn.org

22. Linnoila R.I. et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 1990; 21: 1168-1180.

23. Loh K.C. et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648-658.